Antidote application: an educational system for treatment of common toxin overdose by Long, J. et al.
Boston University
OpenBU http://open.bu.edu
BU Open Access Articles BU Open Access Articles
2017-08-23
Antidote application: an
educational system for treatment
of common toxin overdose
This work was made openly accessible by BU Faculty. Please share how this access benefits you.
Your story matters.
Version
Citation (published version): J. Long, Y. Zhang, V. Brusic, L. Chitkushev, G. Zhang. 2017. "Antidote
application: an educational system for treatment of common toxin
overdose." ACM-BCB 2017. Boston, USA, 2017-08-20 - 2017-08-23
https://hdl.handle.net/2144/24686
Boston University
Antidote Application: An Educational System for Treatment  
of Common Toxin Overdose 
Jon B. Long 
Metropolitan College, Boston 
University 
808 Commonwealth Ave, Boston, MA 
USA 
longjb@me.com 
Yingyuan Zhang 
Metropolitan College, Boston 
University 
808 Commonwealth Ave, Boston, MA
USA 
zyy2013@bu.edu 
Vladimir Brusic 
School of Medicine and Bioinformatics 
Center, Nazarbayev University 
Astana 
Kazakhstan 
vladimir.brusic@nu.edu.kz 
Lou Chitkushev 
Metropolitan College, Boston 
University 
808 Commonwealth Ave, Boston, MA 
USA 
ltc@bu.wsu 
Guanglan Zhang 
Metropolitan College, Boston 
University 
808 Commonwealth Ave, Boston, MA
USA 
guanglan@bu.edu 
 
ABSTRACT 
Poisonings account for almost 1% of emergency room visits each 
year. Time is a critical factor in dealing with a toxicologic 
emergency. Delay in dispensing the first antidote dose can lead 
to life-threatening sequelae. Current toxicological resources that 
support treatment decisions are broad in scope, time-consuming 
to read, or at times unavailable. Our review of current 
toxicological resources revealed a gap in their ability to provide 
expedient calculations and recommendations about appropriate 
course of treatment. To bridge the gap, we developed the 
Antidote Application (AA), a computational system that 
automatically provides patient-specific antidote treatment 
recommendations and individualized dose calculations. We 
implemented 27 algorithms that describe FDA (the US Food and 
Drug Administration) approved use and evidence-based 
practices found in primary literature for the treatment of 
common toxin exposure. The AA covers 29 antidotes 
recommended by Poison Control and toxicology experts, 19 
poison classes and 31 poisons, which represent over 200 toxic 
entities. To the best of our knowledge, the AA is the first 
educational decision support system in toxicology that provides 
patient-specific treatment recommendations and drug dose 
calculations. The AA is publicly available at http://projects.met-
hilab.org/antidote/. 
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1 INTRODUCTION 
In medicine, drug information is presented in many forms such 
as FDA (the US Food and Drug Administration) approved 
package inserts, drug monographs, primary and tertiary 
literature, clinical decision support systems, and electronic drug 
information databases. In emergency situations due to poisoning, 
communication of salient drug information such as indication, 
dosing, and other essential information is important in the rapid 
delivery of lifesaving medical interventions.  
Package inserts or drug monographs are the primary source 
for FDA approved drug dosing and drug use information. 
Though informative, they are not readily searchable, and 
consequently cumbersome to utilize in emergency situations. 
Primary literature, though peer reviewed, requires evaluation on 
the part of the reader for accuracy and appropriateness. Generic 
and toxicology focused clinical decision support systems (CDSS) 
and electronic drug databases do not include algorithms to 
combine drug information with patient specific treatment 
recommendations. Some CDSS do perform dose calculations, but 
to our knowledge none do both treatment recommendation and 
patient-specific dose calculation. This requires the user to 
manipulate patient information and calculate drug dosage, 
resulting in increased possibility of error and delays in antidote 
dispensing. A computational system that takes patient 
information into consideration, automatically provides treatment 
recommendations, and calculates individualized drug dosage will 
reduce medical error and “time to first dose.” 
Regional Poison Control Centers in the U.S. are an 
exceedingly useful tool that clinicians can rely on in a poisoning 
emergency. However, they are only available via telephone, 
which is dependent on the reliability of telecommunication 
providers. As of Dec 2015, the American College of Medical 
Toxicology listed only 177 licensed physicians in the Directory 
of Inpatient Medical Toxicology Services within the U.S. and 
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most of them are clustered in major metropolitan areas 
(http://www.acmt.net/cgi/page.cgi/findtoxicologist.html). 
Licensed physicians who specialize in toxicology are either very 
few or non-existent in non-metropolitan areas. 
There have been a few descriptions in the literature that 
describe the creation of clinical decision support systems that 
specifically address poisonings. In 1985, Rubens described a rule-
based system that focuses on an in-home first response 
algorithm for accidental poisonings in children [1]. In 1994 
Darmoni and coauthors described an expert system in toxicology 
developed for a regional hospital in France that focused on 
diagnosis of poisoning arising from medication overdose and 
gave general treatment recommendations with no patient 
specific dose calculations [2]. In 2010, a group in Malaysia 
developed a system that focused on poisoning diagnosis [3]. 
However none of these three expert systems are publically 
available. 
To bridge the current gap in resources, we created the 
Antidote Application (AA), a computational system that 
automatically recommends individualized antidote treatment 
regimen and patient-specific doses for all age groups ranging 
from newborns to elderly adults. The AA was implemented in 
two formats: a standalone downloadable application for offline 
use (hereinafter referred to as Java AA) and an online web 
application (hereinafter referred to as Web AA). The AA hosts 27 
algorithms for the treatment of common toxin exposure in North 
America. It covers the 29 antidotes recommended by Dart et al. 
[4], for treatment of poisonings by 31 specific toxins and 19 toxin 
classes. These specific toxins and toxin classes represent over 
two hundred toxic entities covered by this system. Phone 
numbers and links to regional PCCs and the federal adverse 
event reporting mechanism (FAER) are included in the AA. The 
AA represents a unique educational resource for treatment of 
common toxin overdose and is current as of May 2016. 
2 MATERIALS AND METHODS 
2.1 Implementation of Algorithms 
In the AA, we implemented 27 algorithms for the treatment of 
common toxin exposure. The list of antidotes included in the AA 
was derived from an expert panel consensus document published 
in the Annals of Emergency Medicine in 2009 that recommends 
antidote formulary inclusions for hospitals as shown in the 
Antidotes and Poisons Table at http://projects.met-
hilab.org/antidote/#/FAQ [4]. The formulary antidote 
recommendations are specific for North American Hospitals. 
For dose calculations, the FDA approved dosing guidelines 
published by the manufacturers were used, whenever available. 
However, not all antidotes described by the expert panel had 
FDA approved indications and usage because some indications 
have been “grandfathered” as accepted practice after the FDA 
clarified the language on indications [5, 6]. Furthermore, the 
number of studies focusing on antidotes or medication 
poisonings in infants and children is small. At times the FDA 
approved indications can be so broad that there is debate on 
whether or not toxicity is an approved indication [7, 8]. For these 
antidotes, several off-label or unapproved-use algorithms 
reported in primary literature references were included in the 
AA in accordance with the FDA guidelines of the “Off-Label” use 
of marketed drugs [9]. We made every effort to avoid using 
tertiary literature because the survey of 17 major sources during 
AA development and implementation yielded inconsistencies in 
treatment recommendations. The treatment and dose 
recommendation in each algorithm in the AA is clearly labeled 
for its FDA approval status. The algorithms are verified using the 
drug dosing treatment guidelines found in the FDA approved 
antidote’s drug monographs whenever available. In addition, we 
have implemented more advanced treatment guidelines as they 
became available through FDA approved amendments to the 
drug monographs. If no drug monograph is available to verify an 
antidote algorithm, guidelines from primary literature were 
obtained. Once an algorithm is verified, each permutation of the 
treatment and dose recommendations for all age groups and 
special populations were determined. Each antidote algorithm 
has distinct characteristics such as the indication, treatment 
thresholds, or hypersensitivity, which are specifically related to 
the treatment recommendations and dose calculations. All of 
these factors must be considered when determining the correct 
permutation of treatment and dose calculation for each 
individual patient.  
Some medical antidotes described in the AA are used in 
multiple algorithms. These antidotes have multiple indications 
and each can be used under more than one poisoning scenario. 
For example, dimercaprol is used in two algorithms. It is used in 
conjunction with Ca-EDTA to treat lead poisoning and in the 
treatment of heavy metal (arsenic, gold or mercury) toxicity. At 
times multiple antidotes are recommended by one algorithm to 
treat a particular poisoning. One example is the Cyanide 
Antidote Package:  Together amyl nitrite, sodium nitrite and 
sodium thiosulfate are indicated for use as a composite antidote 
in the treatment of cyanide poisoning. In the AA, the use of 
generic and trade names of antidotes follows medical convention 
of not capitalizing generic names and capitalizing brand names. 
For example, Tylenol is a brand name of acetaminophen. 
2.2 User input data validation 
To generate patient-specific dosing recommendations, 
users/trainees are required to enter a patient’s age, weight, and 
height in the input boxes at the AA user interface. To minimize 
typographical errors, we implemented several data validation 
measures. 
First, we implemented numeric data validation so that only 
numeric data and decimal points are allowed. In the Java AA, if 
any data other than numeric data and decimal points is entered, 
the user is notified that the data is invalid and is prompted to 
enter only numeric values. The Web AA ensures valid numeric 
data is to be entered by disabling all keyed entry other than 
numbers and decimal points. 
Second, to validate if the values of a patient’s height, weight, 
and age are in reasonable ranges, the user input values are 
compared to the 2000 CDC Growth Charts for the United States: 
Methods and Development document [10]. Values from the 3rd 
percentile in females (lower limit) to 97th percentile in males 
  
 
 
(upper limit) were used as boundaries for normal range. Census 
data for children from 0 to 24 months old had only the height in 
centimeters and weight in kg available. For all other age groups 
in the Census data the BMI (Body Mass Index) is available. The 
age range used to validate data is zero (a neonate) to 100 years 
old. The flowchart of the data validation algorithm is at 
http://projects.met-hilab.org/antidote/img/data_validation.png. 
The data validation subroutine is triggered every time a user 
inputs a set of patient values and clicks one of the begin buttons. 
If the BMI calculated based on the patient values are out of the 
normal range, the user is given an alert that the data is out of 
range and the option to override the alert or re-enter the data. 
As shown in Fig. 1, 900kg was entered as the value of patient 
weight. The resulting BMI, when compared to the BMI range 
from CDC Growth Charts, was flagged as out of range. 
The default input units for weight and height are metric – 
kilograms (kg) and centimeters (cm). When a user sets the units 
to pound and inch, the weight and height values are 
automatically converted to corresponding metric values in 
kilograms and meters for BMI calculation. The BMI is calculated 
by using Quetelet Index formula described in 1832 by Adolphe 
Quetelet:  
ܤܯܫ = ܹ/ܪଶ (1) 
where W denote patient’s weight in kilograms and H height in 
meters.  
The Body Surface Area (BSA) is calculated using the Gehan 
and George formula:  
ܤܵܣ	(ܩ݁ℎܽ݊	ܽ݊݀	ܩ݁݋ݎ݃݁	݂݋ݎ݉ݑ݈ܽ)
= 	0.0235ܪ଴.ସଶଶସ଺ ∗ ܹ଴.ହଵସହ଺ (2) 
where height (H) is in centimeters, and weight (W) is in 
kilograms [11]. The formula used in the calculation of some 
pediatric dosages is based on the Salisbury rule [11]. When a 
child’s weight (W) is 30kg or less, the dose to be administered is 
equal to 2*W% of the adult dose, according to the Salisbury rule. 
If a patient weighs between 30 to 70 kg, the dose to be 
administered is equal to (30+W)% of the adult dose. For children 
weighing 70kg or more, the adult dose should be administered. 
For example if the patient weighs 20 kg administer 40% of the 
adult dose or if the patient weighs 50 kg administer 80% of the 
adult dose. 
A)  
B) 
Figure 1: Screenshots of the AA showing a data out of 
range message generated by the data validation function. 
A) Screenshot of the standalone Java AA. B) Screenshot of 
the web AA. 
2.3 Description of the Treatment Algorithm 
We implemented 27 algorithms that describe FDA approved use 
and evidence-based practices found in primary literature for the 
treatment of common toxin exposure. The flowcharts of all 
algorithms are available in Web AA. To illustrate the functioning 
of AA we present here one of the most complicated algorithms, 
the Acetylcysteine treatment algorithm. Acetylcysteine is used 
in the treatment of acetaminophen (brand name Tylenol®) 
overdose under FDA approved use. Because of the name 
similarity, to avoid confusion with the antidote acetylcysteine, 
the shorthand abbreviation of APAP is used to represent the 
toxin acetaminophen. In toxic concentrations, APAP saturates 
the glucuronide and sulfate conjugation pathways in the liver. It 
is then metabolized by the liver isozyme CYP2E1 to a potentially 
toxic intermediate metabolite that is quickly conjugated by 
hepatic glutathione to a nontoxic substance. As toxicity is 
sustained, glutathione reserves are depleted and the liver begins 
to build up highly toxic metabolites. If left untreated, liver 
dysfunction ensues [12].The mechanism of action for 
acetylcysteine is to replenish the glutathione reserves by acting 
as a glutathione substitute. It acts as a protectant until the liver 
can replenish the glucuronide and sulfate pathway reserves [12]. 
The major factors being considered in the treatment algorithm 
for APAP toxicity were weight, APAP blood levels, time the 
blood sample was taken, treatment threshold, and the time of 
overdose.  
In 1975 Rumack and Mathew described a treatment threshold 
for APAP toxicity that is represented by its blood concentration 
in a log-linear fashion over time [13]. In those days, 
concentrations above the Rumack and Mathew line, the dashed 
line in Fig. 2, at any given time between 4 and 24 hours after 
APAP exposure were consistent with overdose. Liver 
dysfunction does not become noticeable until 4 hours after 
APAP exposure. Blood concentrations taken earlier than 4 hours 
post exposure can yield a false negative result [13-15]. In 1976 
the FDA defined the treatment line that was 25% below the 
Rumack and Mathew line [15] (the solid line in Fig. 2). The 
treatment line, starting at 150µg/mL at 4 hours, is used in the 
U.S. hospitals to determine treatment of APAP overdose. The 
doses above 4 grams/day in adults and accordingly smaller doses 
in children have a high correlation with liver damage.  
To automate the process of determination of treatment 
threshold at a specific time point, we derived mathematical 
equations based on the nomogram. Using two points on the 
treatment line (150µg/mL at 4hrs and 37.5µg/mL at 12hrs), we 
  
 
 
 
were able to use a pharmacokinetic first order rate equation to 
calculate the elimination rate constant. The following illustrates 
how the rate constant was derived. 
ܥ௧ = ܥ଴݁ି(௞)∆௧ (3) 
ܥ௧
ܥ଴ = 		 ݁
ି(௞)∆௧	 (4) 
݈݊ ܥ௧ܥ଴ = 		−(݇)∆ݐ	 (5) 
−
݈݊ ܥ௧ܥ଴
∆ݐ = 	݇	
(6) 
݇ = 	−
݈݊ 37.5	݉ܿ݃150	݉ܿ݃
8ℎݎ 	
(7) 
݇ = 	0.17329	ℎݎିଵ	 (8) 
where denote the APAP plasma concentration at 4 hours post 
exposure and at time point t respectively, ∆ݐ denotes the time 
elapsed from 4 hours post ingestion to time point t, and k 
represents the elimination rate constant. 
 
Figure 2: Acetaminophen overdose nomogram [14]. 
Next we calculate plasma threshold at a time ≥ 4 hours post 
APAP ingestion using the first order rate equation. This 
threshold is then compared to the APAP plasma concentration of 
the patient to determine if treatment is indicated. 
If the APAP blood concentration observed at time point t (in 
hours post ingestion) is ≥	 (150μ݃/݈݉)݁ି	(଴.ଵ଻ଷଶଽ)(௧ି	ସ௛௢௨௥௦) , 
then treatment is indicated. For example an APAP concentration 
of 135mcg/ml at 5 hours post exposure is above the treatment 
threshold (150݉ܿ݃/݈݉)݁ି(଴.ଵ଻ଷଶଽ)(ହ	௛௢௨௥௦ି	ସ௛௢௨௥௦)  or 
126µg/mL. Thus acetylcysteine therapy is indicated. 
Oral dosing for acetylcysteine includes a loading dose of 
140mg/kg PO once, followed by 70mg/kg every 4 hours for 17 
doses. Intravenous dosing includes 150mg/kg (maximum of 
15000mg) IV over 60 minutes followed by 50mg/kg (maximum 
5000mg) IV over four hours followed by 100mg/kg (maximum 
10000mg) IV over 16hours. 
It is also suggested that activated charcoal should be 
administered orally to patients within 4 hours of suspected 
overexposure to APAP. This prevents further gastrointestinal 
absorption of APAP. Administration of activated charcoal 4 or 
more hours after exposure has little to no benefit [15]. 
In the algorithm that we implemented, there are a number of 
possible outcomes as shown in Fig. 3. The Data Validation 
flowchart connects to the flowchart in Fig. 3 A. 
 
 
A) 
 
  
 
 
 
B) 
Figure 3: Acetylcysteine algorithm and subroutines. A) 
The main program. B) The subroutines for dose 
calculation of activated charcoal and acetylcysteine. 
3 RESULTS AND DISCUSSION  
This section summarizes the key factors considered when 
choosing the programming language and architecture of the Java 
AA and Web AA. The Java AA may be downloaded from 
http://projects.met-hilab.org/antidote/antidote_application.jar. In 
the Mac and Windows OS, once downloaded the application may 
be ran by right clicking on the antidote_application.jar file in 
Finder. The security settings in the Mac and Windows OS will 
alert the user that the application is from an unidentified 
developer – this warning can be ignored. The application will 
begin by right clicking “open”.  
3.1 Standalone downloadable AA 
implementation 
When considering a programming language for the standalone 
Antidote application, Java was an immediate favorite. There are 
a number of features that Java offers that are of great benefit to 
the AA. Java is platform independent, which means the code, can 
be written once and used on many different operating systems. 
Java programs are runnable on the Windows, Mac OS X, and 
Linux operating systems. Java is also object oriented, which 
allows code to be reused by other programs. This is of significant 
advantage and is used extensively in the Java AA. The parent 
Antidote class is a repository for many pieces of code used 
throughout the many child classes of the Java AA. For example 
the code for calculating doses based on body surface area (BSA) 
is located and called from the Antidote class. Java is relatively 
easy to learn and maintain. Since Java has a minimal number of 
keywords that are in natural-language syntax, Java is simpler to 
learn than some other languages. Also, as Java applications do 
not need to be rewritten for different platforms or operating 
systems, maintenance updates are easier to implement. Android, 
the mobile operating system is also based on Java. This is 
important as we plan to extend the AA project in the mobile 
application sphere. 
The structure of the Java AA was kept very lean and simple. 
There is a parent class known as the Antidote class. The 
Antidote class contains instance variables and methods that are 
inherited by all of the child classes. The 27 child classes include 
the instance variables (attributes) and methods specific to each 
antidote algorithm. The graphical user interface class controls 
the flow of information between the user and the Java AA. The 
UML (Unified Modeling Language) diagram in Fig. 4 shows this 
relationship. 
 
Figure 4: Antidote Application UML diagram.  
  
 
 
 
 
Figure 5: Architectural data flow diagram of the web AA. 
 
Figure 6: A screenshot showing the individualized 
treatment recommendation for acetylcysteine by the web 
AA. 
When the Java AA is initiated, the antidote GUI interface is 
called and the user is presented with the main page of the 
program and prompted to enter the patient’s age, weight, and 
height. The user is also prompted to select the algorithm of 
interest by choosing an antidote or the corresponding toxin if 
the user knows the cause of toxicity but unsure of the antidote. 
After user input data from the GUI is validated as described in 
section 2.2, the appropriate antidote class is called from the 
antidote class library. Any alerts or messages concerning the 
algorithm that need to be conveyed or if further data is required 
from the user, JOptionPane message or input windows are used 
from the javax.swing package. The return output in the form of a 
string is displayed in the text area of the GUI. At any point in 
time the user can select an antidote from the antidote dropdown 
scrollbar and click the references button to view the references 
of that particular antidote algorithm. 
3.2 Web-based Antidote Application 
The Web AA user interface, calculations and recommendations 
parallel the Java AA. Several web development technologies such 
as JavaScript, jQuery, HTML, CSS, Ajax, and AngularJS were 
employed. It is a client-side application, meaning that all 
computations are processed on the client’s computer. The Web 
AA uses a Model-View-Controller (MVC) architecture, a 
software architectural pattern for implementing user interfaces. 
It divides a software application into three interconnected parts - 
the model consists of the application logic, the controllers are 
responsible for manipulating data, and views present the data 
generated by the user inputs and controller/model outputs. In 
the Web AA the model consists of the antidote algorithms, the 
views are the graphical representations, the controller 
manipulates the model and the view. The controller passes user 
inputs from the view to the model (antidote algorithms) and 
communicates the model outputs to the user. The separation into 
these distinct entities improves the extensibility and 
maintainability of the Web AA. Fig. 5 is a graphical 
representation the MVC relationship. Fig. 6 is a screenshot from 
the Web AA. It demonstrates the decision making process 
following the acetylcysteine algorithm (Fig. 3) for the treatment 
of acetaminophen toxicity. The patient was overdosed with 
APAP eight hours before the blood sample was taken. The 
acetaminophen blood plasma level was 200 µg/mL, which was 
above 75 µg/mL, the treatment threshold at 8 hours after 
overdose. Thus acetylcysteine treatment is recommended and 
individualized drug dosages, highlighted in red in Fig. 6, were 
calculated.  Tutorials on how to use the web AA are available at 
http://projects.met-hilab.org/antidote/#/FAQ.  
3.3 Discussion 
We successfully implemented 27 algorithms for the treatment of 
common poison exposure in North America in both the Java AA 
and the Web AA. The Java AA is a robust, stable and easily 
maintainable system available offline as a standalone expert 
system. It is compatible with all leading operating systems e.g. 
MS Windows, Mac OS X, and Linux. It contains 31 classes, 200 
methods, and 2831 lines of code. The average cyclomatic 
complexity is low (3.337) as well as the average nested block 
depth (1.45). The Java AA standalone system can be downloaded 
at http://www.met-
hilab.org/files/antidote/antidote_application.jar. 
The Web AA has the same cyclomatic complexity and 
average nested block depth as the Java AA. The Web AA 
contains 2443 lines of code, 34 classes and 200 methods. The web 
AA is publically available at http://projects.met-
hilab.org/antidote/. 
These 29 antidotes, 31 specific toxins and 19 toxin classes 
covered in AA are the essential antidotes that an expert panel of 
leading clinical toxicologists recommended to be stocked in 
North American hospitals. These specific toxins and toxin 
  
 
 
classes represent hundreds of toxic entities. Many of the 
antidotes in the AA have other clinically approved and 
unapproved indications. Atropine for instance is essential in 
advanced cardiac life support (ACLS) [16-18]. Sodium 
bicarbonate is used extensively for many other acute indications 
such as cardiac arrest, shock, severe dehydration, primary lactic 
acidosis, and severe diabetic acidosis, to mention a few [19].  
4 CONCLUSIONS 
The AA is a personalized treatment training system since it 
provides patient-specific treatment recommendations and dose 
calculations for all age groups ranging from newborns to elderly. 
All current electronic drug database systems provide incomplete 
information regarding the antidotes included in the AA. To 
verify this observation we reviewed 14 electronic toxicology 
databases and three quick reference antidote charts. In the area 
of toxicology, patient specific recommendations and calculations 
were largely non-existent. Some of the systems have links to 
calculators. While this is a step in the right direction, the 
calculations are not patient specific, which may result in unclear 
and possibly confusing treatment recommendations.  
Both Java AA and Web AA provide guidance for reporting 
toxic exposures regionally and nationally as required by the 
national accrediting bodies and some states by providing the 
phone number to Poison Control and a link to the FAER. There 
is no federal law regarding the reporting of poisoning to Poison 
Control or the FAER. Some states, however, have adopted 
mandatory reporting of poisoning to Poison Control. Also, the 
Joint Commission, an independent organization authorized by 
the Centers for Medicare and Medicaid Services in the 
accreditation and certification of health organizations, requires 
the reporting of adverse events as a part of its core 
accountability measures [20]. The Joint Commission also 
requires that the toll-free Poison Control phone number be 
readily available throughout the hospital. Making these 
resources readily available assists healthcare organizations in 
complying with state law and support their accreditation effort. 
Of all of the electronic systems and quick reference charts 
reviewed in this work, only Medline Plus, a service of the U.S. 
National Library of Medicine, has both the Poison Control 
number and the link to the FAER.  
Both AA systems have been thoroughly tested and all 
algorithms are fully referenced. Every effort was made to ensure 
that references are up-to-date and that the system is 
operationally robust. 
This application can provide a rapid standard of practice 
solution in an emergency-poisoning situation during the waiting 
time – until poison control or a physician specializing in 
toxicology can respond. The time to first dose is critical in many 
poisoning situations. To the best of our knowledge, the AA is the 
first educational decision support system in toxicology that 
provides patient-specific treatment recommendations and drug 
dose calculations. 
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